Testing nemolizumab for lichen planopilaris
Treatments studied
Part of Skin clinical trials.
This study tests a new medication called nemolizumab for people with lichen planopilaris (LPP), a type of scarring hair loss. It aims to see if the drug can help reduce scalp itching and improve the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with lichen planopilaris (LPP) by a doctor.
- You have moderate to severe scalp itching (average score of 4 or higher on a 0-10 scale in the past week).
- You haven't taken nemolizumab before, and you are not currently on certain medications like JAK inhibitors, biologics, or DMARDs without a washout period.
- You are willing to possibly have a small scalp biopsy for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called delgocitinib, which targets certain enzymes linked to inflammation, in people with central centrifugal cicatricial alopecia (CCCA) or lichen planopilaris (LPP). It aims to see if the drug is safe and if it changes biomarkers (biological signals) related to these conditions.
This study tests if a new drug called nemolizumab can help reduce itch in women with lichen sclerosus (LS) in the genital area. Participants must have tried topical steroids before.
This trial tests a new medication called brepocitinib to treat lichen planopilaris (LPP), a condition that causes scarring and hair loss on the scalp. The study aims to see if this drug can reduce symptoms and help hair regrow.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This trial tests a pill called upadacitinib (a JAK inhibitor) for people with erosive lichen planus affecting the mouth or scalp. It aims to see if the drug can reduce inflammation and improve symptoms when topical steroids aren't enough.
This trial compares two medications, hydroxychloroquine and methotrexate, to see which works better for treating lichen planopilaris (a scalp condition that causes hair loss). Patients can choose their treatment or be assigned based on their health needs.
Hear when a new Lichen Plano-Pilaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.